Actively Recruiting
Phase 1 Open-Label Study Evaluating Pharmacokinetics of Mirdametinib in Participants With Moderate or Severe Liver Impairment and Healthy Controls
Led by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · Updated on 2026-10-14
32
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how the body absorbs, breaks down, and removes the drug mirdametinib and its metabolite PD-0315209 in people with moderate or severe liver impairment compared to those with normal liver function. The study also aims to evaluate how well participants tolerate the drug and any side effects they may experience. This research focuses on understanding the drugs behavior in different liver conditions and is not intended to treat any medical condition. Participants will receive a single oral dose of 4 mg mirdametinib on Day 1. The study groups include people with moderate hepatic impairment, severe hepatic impairment, and healthy participants with normal liver function. Each participant undergoes detailed blood sampling over several days to measure drug levels at multiple time points up to 168 hours after dosing. During the study, participants will have assessments including physical exams, vital signs, electrocardiograms, and laboratory tests at screening, before dosing, and after treatment. Researchers will closely monitor the drug concentration in the blood and observe safety and tolerability up to 32 days after dosing. The total study duration covers screening, treatment, and follow-up periods ending on October 31, 2026.
CONDITIONS
Brief Title
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
Research Team
U
US Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here